Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Arnidol is a line of natural topical health products developed by Diafarm, a subsidiary of Faes Farma, primarily targeted at the pediatric market for the treatment of minor bumps and skin irritations. The core product, Arnidol Gel Stick, utilizes a combination of Arnica (*Arnica montana*) and Devil's Claw (*Harpagophytum procumbens*) extracts. Arnica is rich in helenalin, which possesses anti-inflammatory properties by inhibiting the NF-kappaB signaling pathway, while Devil's Claw contains harpagosides that inhibit COX-2 activity. Together, these ingredients work to soothe the skin, reduce swelling, and provide mild analgesic effects following minor physical trauma. The brand has expanded to include specialized products like Arnidol Pic (for insect bites), Arnidol Sun (mineral sun protection), and Arnidol Active Gel (for muscle recovery).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Arnidol.